PDCD1 and neoplasm: Moreover, modern immunotherapies have been recently developed which target against PD-1, PD-L1, or CTLA-4, which disable the ability of tumor cells to evade the immune system without any significant side effects, especially in mRCC (Motzer et al., 2018, 2019; Rini et al., 2019).